Cellectar Biosciences Analyst Ratings
Cellectar Biosciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/04/2022 | 110.53% | HC Wainwright & Co. | $3 → $4 | Maintains | Buy |
| 07/18/2022 | 189.47% | Oppenheimer | → $5.5 | Assumes | → Outperform |
| 07/01/2020 | 163.16% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 06/23/2020 | 57.89% | Maxim Group | → $3 | Initiates Coverage On | → Buy |
| 01/21/2020 | 426.32% | Roth Capital | → $10 | Assumes | → Buy |
| 09/13/2019 | 478.95% | Roth Capital | → $11 | Initiates Coverage On | → Buy |
| 07/30/2019 | 215.79% | Brookline Capital | → $6 | Initiates Coverage On | → Buy |
| 05/02/2019 | 110.53% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2022 年 4 月 11 日 | 110.53% | HC Wainwright & Co. | 3 美元 → 4 美元 | 維護 | 買 |
| 07/18/2022 | 189.47% | 奧本海默 | → 5.5 美元 | 假設 | → 跑贏大盤 |
| 07/01/2020 | 163.16% | 奧本海默 | → 5 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 06/23/2020 | 57.89% | Maxim 集團 | → 3 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 1 月 21 日 | 426.32% | 羅斯資本 | → 10 美元 | 假設 | → 購買 |
| 09/13/2019 | 478.95% | 羅斯資本 | → 11 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 7 月 30 日 | 215.79% | 布魯克林資本 | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2019 年 2 月 5 日 | 110.53% | HC Wainwright & Co. | → 4 美元 | 啓動覆蓋範圍開啓 | → 購買 |
Cellectar Biosciences Questions & Answers
Cellectar 生物科學問題與解答
The latest price target for Cellectar Biosciences (NASDAQ: CLRB) was reported by HC Wainwright & Co. on November 4, 2022. The analyst firm set a price target for $4.00 expecting CLRB to rise to within 12 months (a possible 110.53% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2022年11月4日公佈了Cellectar Biosciences（納斯達克股票代碼：CLRB）的最新目標股價。該分析公司將目標股價定爲4.00美元，預計CLRB將在12個月內升至12個月內（可能上漲110.53％）。去年有兩家分析公司公佈了評級。
The latest analyst rating for Cellectar Biosciences (NASDAQ: CLRB) was provided by HC Wainwright & Co., and Cellectar Biosciences maintained their buy rating.
Cellectar Biosciences（納斯達克股票代碼：CLRB）的最新分析師評級由HC Wainwright & Co. 提供，Cellectar Biosciences維持買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectar Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectar Biosciences was filed on November 4, 2022 so you should expect the next rating to be made available sometime around November 4, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Cellectar Biosciences的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Cellectar Biosciences的最新評級是在2022年11月4日發佈的，因此您應該預計下一個評級將在2023年11月4日左右公佈。
While ratings are subjective and will change, the latest Cellectar Biosciences (CLRB) rating was a maintained with a price target of $3.00 to $4.00. The current price Cellectar Biosciences (CLRB) is trading at is $1.90, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Cellectar Biosciences（CLRB）評級維持不變，目標股價爲3.00美元至4.00美元。Cellectar Biosciences（CLRB）目前的交易價格爲1.90美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。